GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » X4 Pharmaceuticals Inc (NAS:XFOR) » Definitions » EV-to-EBITDA

XFOR (X4 Pharmaceuticals) EV-to-EBITDA : 0.18 (As of Jul. 07, 2025)


View and export this data going back to 2017. Start your Free Trial

What is X4 Pharmaceuticals EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, X4 Pharmaceuticals's enterprise value is $4.66 Mil. X4 Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $25.23 Mil. Therefore, X4 Pharmaceuticals's EV-to-EBITDA for today is 0.18.

The historical rank and industry rank for X4 Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:

XFOR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -13.53   Med: 0.04   Max: 3.21
Current: 0.18

During the past 10 years, the highest EV-to-EBITDA of X4 Pharmaceuticals was 3.21. The lowest was -13.53. And the median was 0.04.

XFOR's EV-to-EBITDA is ranked better than
89.55% of 469 companies
in the Biotechnology industry
Industry Median: 10.03 vs XFOR: 0.18

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-07-07), X4 Pharmaceuticals's stock price is $1.89. X4 Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $2.140. Therefore, X4 Pharmaceuticals's PE Ratio (TTM) for today is 0.88.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


X4 Pharmaceuticals EV-to-EBITDA Historical Data

The historical data trend for X4 Pharmaceuticals's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

X4 Pharmaceuticals EV-to-EBITDA Chart

X4 Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.10 -0.27 -0.42 -0.89 -3.68

X4 Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.73 0.27 -7.24 -3.68 1.27

Competitive Comparison of X4 Pharmaceuticals's EV-to-EBITDA

For the Biotechnology subindustry, X4 Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


X4 Pharmaceuticals's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, X4 Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where X4 Pharmaceuticals's EV-to-EBITDA falls into.


;
;

X4 Pharmaceuticals EV-to-EBITDA Calculation

X4 Pharmaceuticals's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=4.658/25.228
=0.18

X4 Pharmaceuticals's current Enterprise Value is $4.66 Mil.
X4 Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $25.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


X4 Pharmaceuticals  (NAS:XFOR) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

X4 Pharmaceuticals's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.89/2.140
=0.88

X4 Pharmaceuticals's share price for today is $1.89.
X4 Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.140.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


X4 Pharmaceuticals EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of X4 Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


X4 Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
61 North Beacon Street, 4th Floor, Boston, MA, USA, 02134
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Executives
Mark Baldry officer: Chief Commercial Officer C/O AMICUS THERAPEUTICS, 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Christophe Arbet-engels officer: Chief Medical Officer C/O MILLENDO THERAPEUTICS, INC., 110 MILLER AVENUE, SUITE 100, ANN ARBOR MI 48104
Mary Dibiase officer: Chief Operating Officer 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON MA 02134
Paula Ragan director, officer: President and CEO C/O X4 PHARMACEUTICALS, INC., 955 MASSACHUSETTS AVE., 4TH FLOOR, CAMBRIDGE MA 02139
Adam S. Mostafa officer: See Remarks C/O X4 PHARMACEUTICALS INC., 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON MA 02134
Arthur Taveras officer: Chief Scientific Officer C/O X4 PHARMACEUTICALS, INC., 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON MA 02134
Keith Woods director C/O X4 PHARMACEUTICALS INC., 61 NORTH BEACON STREET 4TH FLOOR, BOSTON MA 02134
Michael S Wyzga director RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02139
Murray Stewart director C/O NOVELION THERAPEUTICS INC., 1800-510 WEST GEORGIA STREET, VANCOUVER A1 V6B OM3
Craecker Francoise De director 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON MA 02134
Derek M Meisner officer: General Counsel C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Diego Cadavid officer: Chief Medical Officer C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Alison Frances Lawton director 39 ROBINSON ROAD, LEXINGTON MA 02420
Renato Skerlj officer: Chief Scientific Officer C/O X4 PHARMACEUTICALS, INC., 955 MASSACHUSETTS AVENUE, 4TH FLOOR, CAMBRIGE MA 02139
William Aliski director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949

X4 Pharmaceuticals Headlines

From GuruFocus